Martin Shkreli became infamous for hiking the price of a potentially lifesaving drug by more than 4,000%, then behaving like an insufferable little king who couldn’t understand why anyone objected. He smirked through public outrage, revelled in his reputation as a corporate villain and seemed to treat human suffering as an amusing inconvenience. But behind the obnoxious online persona was something far more serious: a pharmaceutical executive whose illegal business practices helped keep affordable alternatives to essential medication off the market. This wasn’t a misunderstood genius upsetting polite society. It was greed with a smug face and a pharmaceutical licence.
Is a prick because…
- He hiked a lifesaving drug’s price by more than 4,000%. In 2015, Shkreli’s company raised the price of Daraprim, used to treat toxoplasmosis, from $17.50 to $750 per tablet. For vulnerable patients, including people with compromised immune systems, this was not some luxury product becoming more expensive. It was essential medication being turned into an opportunity for enormous profits. Shkreli became the face of everything rotten about putting pharmaceutical profits ahead of patients.
- He didn’t stop at making the drug unaffordable. A federal court found that Shkreli orchestrated an illegal scheme to block generic competitors and protect the inflated price. His company used restrictive distribution arrangements and supply agreements to make it harder for rivals to obtain the ingredients needed to produce cheaper alternatives. In 2022, he was ordered to pay $64.6 million and banned for life from the pharmaceutical industry. The ban was upheld on appeal in 2024.
- He turned public outrage into an ego trip. Rather than showing much humility, Shkreli cultivated his reputation as the smirking villain of the pharmaceutical industry. His provocative online persona made him a media spectacle, but behind the trolling was a real-world business affecting access to medication. Acting like an obnoxious internet genius doesn’t make you clever when the underlying conduct has been found illegal.
- His criminal record goes beyond the drug scandal. Shkreli was convicted in 2017 of securities fraud and conspiracy involving investors in his hedge funds and former pharmaceutical company. He was sentenced to seven years in prison and released in 2022 after serving most of that sentence. His pharmaceutical misconduct and his criminal convictions were separate matters, but together they demolish the idea that he was merely a controversial businessman punished for being unpopular.
- Even a lifetime ban apparently wasn’t the end of the story. In October 2026, the Federal Trade Commission and several states asked a federal court to hold Shkreli in civil contempt, alleging that he had violated the ban through pharmaceutical stock trading and other industry-related activities. Those allegations are still subject to the court process. If the allegations are established, they would show extraordinary disregard for a restriction imposed after a court found serious and deliberate misconduct.
Is not a prick because…
- He was right that pharmaceutical pricing needed scrutiny. The drug industry has genuine problems with competition, access and pricing. Shkreli’s case helped expose them to a wider public. But highlighting a rotten system does not excuse exploiting it, and drawing attention to a problem is hardly a noble achievement when your own conduct becomes one of its clearest examples.
Shkreli became famous because he made it impossible to ignore the uglier side of pharmaceutical capitalism. He raised the price of essential medication, illegally obstructed competition, was convicted of separate financial crimes and received a lifetime ban from the industry he once helped run. His defenders might admire the audacity, but audacity is not a substitute for integrity. When someone treats access to medication as an opportunity to squeeze vulnerable people for profit, the smirk isn’t evidence of genius. It’s just the face he chose to put on greed.
